Veradermics Inc MANE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Veradermics to Present at Upcoming September Investor Conferences
-
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
-
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
-
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout
-
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
-
A new version of an old drug is helping men grow back some of their hair
-
For the first time in decades, new hair-loss treatments are in the works. Here's how they're different.
-
For the first time in decades, new hair-loss treatments are in the works. Here's how they're different.
Trading Information
- Previous Close Price
- $121.23
- Day Range
- $116.04–123.83
- 52-Week Range
- $32.00–131.24
- Bid/Ask
- $114.80 / $130.10
- Shares Outstanding
- 41.78M
- Market Cap
- $4.90B
- Volume/Avg
- 660,187 / 720,268
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 21
- Website
- https://www.veradermics.com
Valuation
|
Metric
|
MANE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.02 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MANE
|
|---|---|
Quick Ratio | 70.25 |
Current Ratio | 70.53 |
Interest Coverage | — |
Quick Ratio
MANE
Profitability
|
Metric
|
MANE
|
|---|---|
Return on Assets (Normalized) | −23.75% |
Return on Equity (Normalized) | −33.55% |
Return on Invested Capital (Normalized) | −36.89% |
Return on Assets
MANE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|vZr<#D | LOCK|&zhP | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!#M%Cj | LOCK|<myGf | $76B | |||
| Moderna Inc
MRNA
| LOCK|h&^C$&n | LOCK|?g | $75B | |||
| argenx SE ADR
ARGX
| LOCK|&?X?#t | LOCK|qb> | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|ZT@@P& | LOCK|S^ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gBbv%p | LOCK|JGjH> | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|X?KD%Q% | LOCK|d#kq | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|z#Y!@L | LOCK|W& | $24B | |||
| Incyte Corp
INCY
| LOCK|#NQn&Y | LOCK|wL | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<kr%$L> | LOCK|#hV | $15B |
United States